Bromantane and Testosterone Interaction: Avoid | Peptide Database

FDA-approved for treatment of essential hypertension as monotherapy or in combination with other antihypertensives. Provides consistent 24-hour blood pressure reduction. Particularly effective for AAS-induced hypertension where elevated blood pressure is driven by RAAS activation and increased erythropoiesis. FDA-approved for reduction of cardiovascular morbidity in patients at high risk. The ONTARGET trial demonstrated non-inferiority to ramipril for the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure in over 25,000 high-risk patients. Angiotensin II receptor blockade counteracts the pro-hypertrophic and pro-fibrotic effects of supraphysiological androgen levels on the myocardium. Preclinical and observational data support the use of ARBs to attenuate left ventricular hypertrophy in steroid users. Widely recommended in harm reduction protocols. Reduces intraglomerular pressure and proteinuria by blocking angiotensin II-mediated efferent arteriolar constriction. Slows progression of chronic kidney disease, particularly in patients with diabetic nephropathy or hypertensive nephrosclerosis. Relevant for AAS users where elevated blood pressure and NSAID co-use may compromise renal function. Telmisartan's partial PPAR-gamma agonism improves insulin sensitivity without the weight gain associated with full PPAR-gamma agonists like pioglitazone. May reduce the risk of new-onset diabetes in hypertensive patients. The metabolic benefit is particularly relevant for users of compounds that impair glucose tolerance (e.g., growth hormone, trenbolone).

Noopept's best-established effect is enhancement of memory consolidation and retrieval. Animal studies consistently demonstrate improved performance on spatial memory, passive avoidance, and novel object recognition tasks. Human studies in patients with mild cognitive impairment and organic brain disorders show improvements in memory scores and attentional capacity. Demonstrated neuroprotective activity in multiple models of neuronal injury including oxidative stress, amyloid-beta toxicity, and glutamate excitotoxicity. The upregulation of BDNF and NGF provides trophic support to vulnerable neuronal populations, which may slow or prevent neurodegeneration. Users commonly report improved clarity of thought and sustained attention. While less studied than memory effects, the modulation of glutamatergic signaling and downstream cholinergic enhancement likely contribute to improved attentional performance. Approved in Russia for cognitive deficits following traumatic brain injury. Clinical trials demonstrated improvements in memory, attention, and emotional stability in patients recovering from cerebral trauma. Approved for cognitive decline associated with cerebrovascular insufficiency. Patients with chronic cerebrovascular disease showed improvements in cognitive test scores and reduction in associated emotional disturbances including anxiety and irritability. Preclinical evidence suggests potential benefits through NGF/BDNF upregulation and inhibition of amyloid-beta aggregation and neurotoxicity. Not yet tested in rigorous clinical trials for Alzheimer's specifically, but the mechanistic rationale is strong. An anxiolytic effect has been observed in both animal models and human clinical use at standard nootropic doses. Unlike benzodiazepines, the anxiolytic effect does not come with sedation or cognitive impairment, making it a potentially useful secondary benefit.